Perspective Therapeutics licenses Mayo Clinic's PSMA Alpha-PET platform for up to $68M milestones

Perspective Therapeutics, Inc.

Upfront cash payment of $1M due within 60 days of Dec 22, 2023; milestone payments up to $68M tied to clinical, regulatory, and commercialization achievements.
Single-digit royalties on net sales of certain Licensed Product components; 40% of any PRV sale proceeds to be shared with Mayo.
Platform uses 64/67 Cu and 203/212 Pb double chelator design for PET imaging and alpha/beta-particle targeted RPT.
Preclinical data showed favorable salivary gland uptake and kidney clearance vs. comparators; initial focus on PSMA-expressing prostate cancer.
Mayo Clinic holds financial interest in the technology; Perspective must use commercially reasonable efforts to bring Licensed Products to market.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Perspective Therapeutics, Inc. entered into Exclusive Patent License Agreement with Mayo Foundation for Medical Education and Research valued at upfront payment of $1 million, milestone payments up to $68 million, single digit royalties on net s (effective 2023-12-31).

Action: entry
Agreement: license
Counterparty: Mayo Foundation for Medical Education and Research
Value: upfront payment of $1 million, milestone payments up to $68 million, single digit royalties on net s
Effective: 2023-12-31

Exact text from the filing

On December 31, 2023, Perspective Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an exclusive patent license agreement (the “ License Agreement ”) with the Mayo Foundation for Medical Education and Research (“ Mayo Clinic ”).

View on SEC.gov

Browse all material agreements →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-000752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.